Vitamin D status after a high dose of cholecalciferol in healthy and burn subjects

Rousseau, Anne-Françoise; Damas, Pierre; Ledoux, Didier; Lukas, Pierre; Carlisi, Agnès; Goff, Caroline Le; Gadisseur, Romy; Cavalier, Étienne

doi:10.1016/j.burns.2014.11.011

Cited by 21 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 21 days 106 Cantor, 2014 [ 65 ] 18 Internal medicine patients n.a 356,000 IU as 300,00 IU followed by 4000 IU/day Baseline 22 14 days 102 50–202 ” 32 ” n.a. 206,000 IU as150,000 IU followed by 4000 IU/day Baseline 55 14 days 108 58–185 Kearns et al, 2015 [ 66 ] 14 Healthy volunteers 24 250,000 IU in one dose Baseline 41 5 days 102 70–149 Oliveri et al, 2015 [ 67 ] 11 Healthy volunteers 22 100,000 IU in one dose Baseline 41 SD 12 7 days 105 ” 11 ” 21 100,000 IU vitamin D2 in one dose Baseline 41 SD 28 7 days 92 Rousseau et al, 2015 [ 68 ] 29 Healthy volunteers n.a. 100,000 IU in one dose Baseline 54 7 days 100 64–167 ” 20 Acute burn injury n.a.…”

Section: Resultsmentioning

confidence: 99%

Appropriate vitamin D loading regimen for patients with advanced lung cancer

Hoffer

Robitaille

Swinton

et al. 2015

Nutr J

View full text Add to dashboard Cite

BackgroundMost patients attending cancer clinics have hypovitaminosis D. Correcting or preventing this abnormal condition could mitigate the emotional and physical complications of their disease, but clinical trials of vitamin D therapy in this setting are hindered by the unavailability of safe, effective and practical loading dose regimens.MethodsIn this single arm open-label pharmacokinetic trial, outpatients with advanced lung cancer consumed 20,000 IU vitamin D daily with the largest meal of the day for 14 days followed by 10,000 IU per day for a further 7 days. Plasma concentrations of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone, calcium, vitamin C and C-reactive protein were measured on protocol days 0, 14 and 21, and serum vitamin D binding protein (VDBP) concentrations on days 0 and 21. As a secondary objective, preliminary information was obtained regarding clinical effects of rapid vitamin D loading on mood and symptoms by administering appropriate questionnaires two times at baseline and after 14 and 21 days of vitamin D therapy.ResultsOf the 91 patients enrolled in the study, 85 % had hypovitaminosis D and 41 % had hypovitaminosis C. Plasma VDBP concentrations were in the normal range. The vitamin D load increased the average plasma 25(OH)D concentration to 116 ± 34 nmol/L (mean ± SD); the median concentration was 122 nmol/L (interquartile range 103–134); VDBP concentrations did not change. Final plasma 25(OH)D concentrations were subnormal (<75 nmol/L) for 13 % of the patients and sub-target (<120 nmol/L) for 44 % of them. In most cases, subnormal and sub-target 25(OH)D concentrations were attributable to obesity and/or a low baseline 25(OH)D concentration. Mood and symptom scores did not change significantly throughout the 3-week protocol.ConclusionHypovitaminosis D and C are very common in outpatients with advanced lung cancer. A vitamin D load of 20,000 IU per day for 14 days failed to achieve the target concentration in 44 % of the participants in this trial. These results suggest that a loading dose of 30,000 IU per day for 14 days would be safe and effective for patients who are obese or at risk of severe hypovitaminosis D. The preliminary nature of the study design, and the failure to achieve target 25(OH)D concentrations for a large proportion of the patients, do not allow any firm conclusion about the clinical effects of correcting hypovitaminosis D in this patient population. Nevertheless, no evidence was obtained that partial correction of hypovitaminosis D greatly improved mood, reduced distress or relieved cancer-related symptoms. This trial was registered at clinicaltrials.gov as NCT01631526.

show abstract

Section: Resultsmentioning

confidence: 99%

Appropriate vitamin D loading regimen for patients with advanced lung cancer

Hoffer

Robitaille

Swinton

et al. 2015

Nutr J

View full text Add to dashboard Cite

show abstract

“…There were 2 women and 18 men. Median age was 44 (19-86) years old, median BSA reached 15 (7-85) % and median ABSI (Abbreviated Burns Severity Index) score was 5 [4][5][6][7][8][9][10][11][12]. Of the enrolled patients, 8 were discharged before the end of the protocol.…”

Section: Resultsmentioning

confidence: 99%

“…From another point of view, burn has repercussions on VD synthesis due to skin damage and, later, strategies to prevent abnormal scarring following burn healing (sunlight eviction and pressure garments). Furthermore, alterations of VD physiology and metabolism may be suspected in severe burn patients who are thus at high risk of VD deficiency [5]. Given its role in P and VD metabolism, it may be therefore relevant to focus on FGF23 in the particular context of burn.…”

Section: Introductionmentioning

confidence: 99%

Fibroblast growth factor 23 in acute burn patients: Novel insights from an intact-form assay

Rousseau

Souberbielle²,

Delanaye

et al. 2016

Burns

Self Cite

View full text Add to dashboard Cite

“…Severe burn results in acute bone resorption followed by a dynamic state, most likely due to changes brought about by the inflammatory and glucocorticoid responses to the injury (Klein et al, 2015). Recent studies found increased FGF23 in adult burn patient, suggesting that osteocytes may be apoptotic (Klein et al, 2015;Rousseau, 2015). Moreover, an interesting correlation between CRP and FGF23 was found (Rousseau et al, 2014).…”

Section: Burnsmentioning

confidence: 98%

Fibroblast Growth Factor 23: Review of its role in Clinical Medicine

2016

European Journal of Medicine

View full text Add to dashboard Cite

In the last decade, there is an ongoing interest about Fibroblast growth factor-23. Its clinical significance seems to go far beyond hereditary disease. The current review presents the newest findings about this factor in several fields of medicine. Along with its undoubted place in hereditary bone diseases and renal failure, in every stage, FGF23 role is far beyond clear. Further studies are needed to determine its place as prognostic, diagnostic or severity biomarker.

show abstract

Vitamin D status after a high dose of cholecalciferol in healthy and burn subjects

Cited by 21 publications

References 37 publications

Appropriate vitamin D loading regimen for patients with advanced lung cancer

Appropriate vitamin D loading regimen for patients with advanced lung cancer

Fibroblast growth factor 23 in acute burn patients: Novel insights from an intact-form assay

Fibroblast Growth Factor 23: Review of its role in Clinical Medicine

Contact Info

Product

Resources

About